A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo

David M. Markovitz(University of Michigan), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Chris Chun-Yiu Chan(University of Hong Kong), Dafydd Thomas(University of Michigan), Lisa Hain(Johannes Kepler University of Linz), Ko‐Yung Sit(Queen Mary Hospital), Kelvin Kai‐Wang To(Hong Kong Science and Technology Parks Corporation), Shuofeng Yuan(University of Hong Kong - Shenzhen Hospital), Peter Hinterdorfer(Johannes Kepler University of Linz), Huiping Shuai(University of Hong Kong), Hin Chu(University of Hong Kong), Jasper Fuk‐Woo Chan(Hong Kong Science and Technology Parks Corporation), Daniel Canena(Johannes Kepler University of Linz), Chris Oostenbrink(BOKU University), Jinxia Zhang(Peking University), Miriam Klausberger(Institute of Molecular Biotechnology), Maureen Legendre(University of Michigan), Josef Penninger(Helmholtz Centre for Infection Research), Yuxin Hou(University of Hong Kong), Rong Zhu(Johannes Kepler University of Linz), Johannes Stadlmann(BOKU University), Jian‐Piao Cai(University of Hong Kong), Wan-Mui Chan(University of Hong Kong), Yoo Jin Oh(Johannes Kepler University of Linz), Cuiting Luo(University of Hong Kong), Man Lung Yeung(Hong Kong Science and Technology Parks Corporation), Yixin Wang(Mudanjiang Normal University), Kwok‐Hung Chan(University of Hong Kong), Lei Wen(University of Hong Kong), Kenn Ka Heng Chik(University of Hong Kong), Vincent Kwok‐Man Poon(Queen Mary Hospital), Wing‐Kuk Au(Queen Mary Hospital), Chris Chung‐Sing Chan(University of Hong Kong)
Research Square
May 17, 2021
Cited by 2


Related Papers